Nektar Therapeutics Reports First Quarter 2026 Financial Results
Nektar Therapeutics reported Q1 2026 financial results with $10.9 million in revenue and a net loss of $44.9 million. The company's cash and investments in marketable securities on March 31, 2026, were $731.6 million, excluding $351 million in net proceeds from a secondary offering completed in April 2026.
Key figures
- Revenue
- 10900000
- Cash and investments
- 763271000
- Research and development expense
- 35680000
- General and administrative expense
- 13439000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.